"Jan. 8, 2013 -- Parkinson's disease itself doesn't seem to raise a person's risk for compulsive addictions to things like gambling, shopping, or sex, a new study shows.
Compulsive behaviors affect about 14% of Parkinson's patients tre"...
- Patient Information:
Details with Side Effects
ZELAPAR® (selegiline hydrochloride) is indicated as an adjunct in the management of patients with Parkinson's disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that ZELAPAR® (selegiline hydrochloride) has any beneficial effect in the absence of concurrent levodopa therapy.
DOSAGE AND ADMINISTRATION
ZELAPAR® (selegiline hydrochloride) is intended for administration to patients with Parkinson's disease receiving levodopa/carbidopa therapy who demonstrate a deteriorating response to this treatment.
Treatment should be initiated with 1.25 mg given once a day for at least 6 weeks. After 6 weeks, the dose may be escalated to 2.5 mg given once a day if a desired benefit has not been achieved and the patient is tolerating ZELAPAR® (selegiline hydrochloride) . There is no evidence that doses greater than 2.5 mg a day confer any additional benefit, and they should ordinarily be avoided because of the potential increased risk of adverse events.
ZELAPAR® (selegiline hydrochloride) should be taken in the morning before breakfast and without liquid.
In the controlled trial of ZELAPAR® (selegiline hydrochloride) in which ZELAPAR® (selegiline hydrochloride) was shown to be effective compared to placebo, 17% of patients in the ZELAPAR® (selegiline hydrochloride) group and 19% of patients in the placebo treatment group had a reduction in their doses of levodopa/carbidopa because of perceived dopaminergic side effects. For those patients with a dose reduction, the average reduction was 24% for ZELAPAR® (selegiline hydrochloride) and 21% for placebo.
Patients should not attempt to push ZELAPAR® (selegiline hydrochloride) through the foil backing. Patients should PEEL BACK the backing of one or two blisters (as prescribed) with dry hands, and GENTLY remove the tablet(s). Patients should IMMEDIATELY place the ZELAPAR® (selegiline hydrochloride) tablet(s) on top of the tongue where it will disintegrate in seconds. Patients should avoid ingesting food or liquids for 5 minutes before and after taking ZELAPAR® (selegiline hydrochloride) .
ZELAPAR® (selegiline hydrochloride) Orally Disintegrating Tablets are available containing 1.25 mg selegiline hydrochloride in a Zydis® formulation. Each pale yellow tablet is imprinted with a stylized “V”. Ten tablets are contained in a moisture-resistant pouch and packaged in a carton. Neither the blister card nor the pouch is child-resistant.
ZELAPAR® (selegiline hydrochloride) is available as: NDC 0187-0453-02, carton of 6 pouches (60 tablets).
Store at controlled room temperature, 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Use within 3 months of opening pouch and immediately upon opening individual blister. Store blister tablets in pouch. Potency cannot be guaranteed after 3 months of opening the pouch.
ZELAPAR® (selegiline hydrochloride) 1.25 mg Orally Disintegrating Tablets are manufactured for: VALEANT™ Pharmaceuticals North America, Aliso Viejo, CA 92656, USA. By: Cardinal Health, Inc. Swindon, Wiltshire, SN5 8RU, UK. Rev. February 2008
Last reviewed on RxList: 2/19/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Zelapar Information
Zelapar - User Reviews
Zelapar User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get breaking medical news.